Article

FDA approves Lenstec IOL

The FDA has approved a new IOL (Softec HD, Lenstec) for patients with cataracts.

St. Petersburg, FL

-The FDA has approved a new IOL (Softec HD, Lenstec) for patients with cataracts.

The lens already is in use throughout the European Union, Australia, Canada, China, and other international markets. More than 1 million of the IOLs have been implanted worldwide since 2005, according to its maker, which also maintains that the IOL is manufactured with a tolerance of 0.125 D.

“Lens variability is one of the leading causes of refractive error for patients who undergo cataract surgery,” said Jim Simms, Lenstec vice president.

The company’s technology reduces variability and enables surgeons to target each patient's prescription better, he added.

In addition to reducing variability, the company’s manufacturing process makes it possible to produce the lenses in 0.25-D increments for prescriptions from +18 to +25 D, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.